287 reports of this reaction
1.2% of all BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE reports
#19 most reported adverse reaction
VISUAL IMPAIRMENT is the #19 most commonly reported adverse reaction for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, manufactured by AstraZeneca Pharmaceuticals LP. There are 287 FDA adverse event reports linking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE to VISUAL IMPAIRMENT. This represents approximately 1.2% of all 23,211 adverse event reports for this drug.
Patients taking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE who experience visual impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISUAL IMPAIRMENT is a less commonly reported adverse event for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, but still significant enough to appear in the safety profile.
In addition to visual impairment, the following adverse reactions have been reported for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE:
The following drugs have also been linked to visual impairment in FDA adverse event reports:
VISUAL IMPAIRMENT has been reported as an adverse event in 287 FDA reports for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISUAL IMPAIRMENT accounts for approximately 1.2% of all adverse event reports for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, making it a notable side effect.
If you experience visual impairment while taking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.